Byung Ho Lee

Dr. Byung Ho Lee

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2006 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
MYMi Young Yoo
Mi Young Yoo
KOKwang-Seok Oh
Kwang-Seok Oh
JLJung Won Lee
Jung Won Lee
HSHo Won Seo
Ho Won Seo
GYGyu Hwan Yon
Gyu Hwan Yon
BLByung Ho Lee
Byung Ho Lee

17 October 2003 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
MKMyung‐Ja Kwon
Myung‐Ja Kwon
KJKyu‐Shik Jeong
Kyu‐Shik Jeong
ECEun Jeong Choi
Eun Jeong Choi
BLByung Ho Lee
Byung Ho Lee

1 November 2016 in International Immunopharmacology
Verified
Journal Article
Closed access
JLJeong Hyun Lee
Jeong Hyun Lee
BPByung Kil Park
Byung Kil Park
KOKwang-Seok Oh
Kwang-Seok Oh
KYKyu Yang Yi
Kyu Yang Yi
CLChae Jo Lim
Chae Jo Lim
BLByung Ho Lee
Byung Ho Lee

1 July 2006 in European Journal of Pharmacology
Verified
Journal Article
Closed access
GHGeum Shil Hwang
Geum Shil Hwang
KOKwang-Seok Oh
Kwang-Seok Oh
HKHyun-Na Koo
Hyun-Na Koo
HSHo Won Seo
Ho Won Seo
KYKwan-Hee You
Kwan-Hee You
BLByung Ho Lee
Byung Ho Lee

23 July 2008 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
SRShi Yong Ryu
Shi Yong Ryu
KOKwang-Seok Oh
Kwang-Seok Oh
YKYoung Sup Kim
Young Sup Kim
BLByung Ho Lee
Byung Ho Lee

19 January 2015 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
KOKwang-Seok Oh
Kwang-Seok Oh
JLJ H Lee
J H Lee
KYK Y Yi
K Y Yi
CLC J Lim
C J Lim
SLS Lee
S Lee
BLByung Ho Lee
Byung Ho Lee
Background and Purpose: Blockade of the actions of urotensin‐II (U‐II) mediated by the urotensin (UT) receptor should improve cardiac function and prevent cardiac remodelling in cardiovascular disease. Here, we have evaluated the pharmacological properties of the recently identified UT receptor antagonist, 2‐(6,7‐dichloro‐3‐oxo‐2H‐benzo[b][1,4]oxazin‐4(3H)‐yl)‐N‐methyl‐N‐(2‐(pyrrolidin‐1‐yl)‐1‐(4‐(thiophen‐3‐yl)phenyl) ethyl)acetamide (KR36676).Experimental Approach: Pharmacological properties of KR36676 were studied in a range of in vitro assays (receptor binding, calcium mobilization, stress fibre formation, cellular hypertrophy) and in vivo animal models such as cardiac hypertrophy induced by transverse aortic constriction (TAC) or myocardial infarction (MI).Key Results: KR36676 displayed high binding affinity for the UT receptor (Ki: 0.7 nM), similar to that of U‐II (0.4 nM), and was a potent antagonist at that receptor (IC50: 4.0 nM). U‐II‐induced stress fibre formation and cellular hypertrophy were significantly inhibited with low concentrations of KR36676 (≥0.01 μM). Oral administration of KR36676 (30 mg·kg−1) in a TAC model in mice attenuated cardiac hypertrophy and myocardial fibrosis. Moreover, KR36676 restored cardiac function and myocyte size in rats with MI‐induced cardiac hypertrophy.Conclusions and Implications: A highly potent UT receptor antagonist exerted anti‐hypertrophic effects not only in infarcted rat hearts but also in pressure‐overloaded mouse hearts. KR36676 could be a valuable pharmacological tool in elucidating the complicated physiological role of U‐II and UT receptors in cardiac hypertrophy.